This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Thalidomide shows promise as a steroid-sparing option for IgG4-related disease, with a significant reduction in relapse rates and enhanced remission, according to a placebo-controlled study.
Medscape Medical News